DailySand LogoDailySand
BlogSearchArchiveTimelineAbout
Today's DigestBlogArchiveTimelineTopicsSearchAboutFAQContact

Content

  • Today's Digest
  • Archive
  • Blog
  • Timeline
  • Topics
  • Search

Tools

  • MCP Server
  • JSON API
  • OpenAPI Spec
  • RSS Feed
  • Sitemap

Company

  • About
  • FAQ
  • Contact

Legal

  • Privacy Policy
  • Terms of Service
  • AI Context (llms.txt)
  • AI Directives
© 2026 DailySand. Not investment advice.Daily AI, Investing & Critical Minerals Intelligence
← All Topics

vaccine development

2 items across 2 digests

Related Daily Digests

After the Export Ban: How AI Exploit Generation Is Forcing a 30-Minute Patch Window

May 11, 2026

The Quiet Shift: MetaClaw's Calendar Training, Cambridge's Million-Fold Power Reduction, and Middle East Supply Chain Risks

March 29, 2026

All Items

FinancialCNBC Tech

Hantavirus cases spark brief surge in pharma and biotech stocks — here’s why trading is so volatile

Hantavirus cases on a cruise ship sparked surges in biotech and pharmaceutical stocks as firms develop vaccines. This demonstrates how disease outbreak news creates immediate volatility in healthcare sectors, highlighting the speculative nature of pandemic-related trading.

#Hantavirus#biotech stocks#pharmaceutical
Read original →
AIThe Decoder

OpenAI's Sam Altman and Science VP Kevin Weil hype AI-assisted dog cancer story ignoring there's no proof the vaccine worked

OpenAI executives Sam Altman and Kevin Weil promoted an AI-assisted dog cancer vaccine story despite no proof the vaccine actually worked. This highlights the risk of AI hype outpacing scientific validation, potentially undermining trust in AI applications for medical research and diagnostics.

#OpenAI#Sam Altman#AI medical applications
Read original →